Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol.
For an accurate assessment of rifampicin bioequivalence from fixed-dose combinations (FDCs), and to reduce the time and cost constraints associated with bioequivalence studies, the World Health Organization and the International Union Against Tuberculosis and Lung Disease have developed a simplified screening protocol. This study was undertaken with the objective of testing the applicability of this protocol for all types of FDCs. Data were obtained for volunteers common to three studies, and pharmacokinetic parameters were evaluated by different statistical tests. From the results, it has been demonstrated that the simplified screening protocol is suitable for evaluating the bioequivalence of rifampicin in all the types of FDCs available on the market.
Panchagnula
R
R
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab, India. panchagnula@yahoo.com
Agrawal
S
S
Kaur
K J
KJ
Singh
I
I
Kaul
C L
CL
D000328:Adult; D000704:Analysis of Variance; D000904:Antibiotics, Antitubercular / Q000493:pharmacokinetics* / Q000592:standards; D019540:Area Under Curve; D004341:Drug Evaluation / Q000191:economics / Q000379:methods*; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D012293:Rifampin / Q000493:pharmacokinetics* / Q000592:standards; D018401:Sample Size; D013810:Therapeutic Equivalency
D000904:Antibiotics, Antitubercular; D012293:Rifampin